<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Yarnold, John</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The UK START Trials: 10-Year Follow-Up Results</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-9</style></pages><abstract><style  face="normal" font="default" size="100%">The international standard for radiotherapy after primary surgery for early breast cancer has been a total dose of 50 Gy administered in 25 small daily fractions over 5 weeks. However, the randomized UK Standardisation of Breast Radiotherapy [START] trials indicate that a lower total dose delivered in fewer larger fractions is likely to be safe and effective [START Trialists' Group. Lancet 2008; Lancet Oncol 2008]. This article presents the 10-year follow-up results of the UK START trials, which tested 13- and 15-fraction regimens in women with completely excised early breast cancer (T1–3, N0–1, M0).</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>